SCHEMBL2462200

SCHEMBL2462200

N#Cc1nnc(NCc2ccccc2)c2ccc(C(=O)Nc3cccc(C(F)(F)F)c3)cc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 4/20 0.53
RXFP1 Q9HBX9 5/20 0.52
AURKA O14965 2/20 0.49
RPS6KB1 P23443 2/20 0.49
DDR2 Q16832 3/20 0.49
DDR1 Q08345 2/20 0.49
MAPT P10636 2/20 0.47
KCNK3 O14649 1/20 0.47
FLT1 P17948 3/20 0.47
ABL1 P00519 1/20 0.47
EGFR P00533 1/20 0.47
CSF1R P07333 1/20 0.47
PDGFRB P09619 1/20 0.47
KIT P10721 1/20 0.47
FLT4 P35916 1/20 0.47
LMNA P02545 2/20 0.47
MEN1 O00255 1/20 0.45
ALDH1A1 P00352 1/20 0.45
HPGD P15428 1/20 0.45
HTT P42858 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12254176 0.88 AURKA (0.49) KDRAURKARPS6KB1
SCHEMBL12333654 0.86 DDR2 (0.55) KDRRXFP1AURKARPS6KB1DDR2
SCHEMBL2459069 0.86 RXFP1 (0.55) KDRRXFP1AURKARPS6KB1DDR2
SCHEMBL2459016 0.86 RXFP1 (0.55) KDRRXFP1AURKARPS6KB1DDR2
SCHEMBL2462026 0.85 MAPT (0.53) KDRRXFP1MAPTKCNK3CSF1R
SCHEMBL14548726 0.85 RXFP1 (0.53) KDRRXFP1AURKARPS6KB1DDR2
SCHEMBL12333659 0.85 DDR2 (0.55) KDRRXFP1AURKARPS6KB1DDR2
SCHEMBL2457621 0.85 RXFP1 (0.55) KDRRXFP1AURKARPS6KB1DDR2
SCHEMBL2462701 0.85 RXFP1 (0.55) KDRRXFP1AURKARPS6KB1DDR2
SCHEMBL14548725 0.83 RXFP1 (0.53) KDRRXFP1AURKARPS6KB1DDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237571-A1 PHTHALAZINE DERIVATIVES ARALDI GIAN-LUCA 2011-09-29 US claimed
US-8349836-B2 Phthalazine derivatives as inhibitors of protein kinase ARALDI GIAN-LUCA (US) 2013-01-08 US disclosed
US-8044041-B2 e.g. 4-Chloro-1-hydroxy-phthalazine-6-carboxylic acid [4-chloro-3'-(2-dimethylamino-ethoxy)-biphenyl-3-yl]-amide; multifunctioning protein kinase inhibitors; anticarcinogenic, antiinflammatory, antidiabetic agent, neurodegenerative diseases FOREST LABORATORIES HOLDINGS LIMITED (BM) 2011-10-25 US disclosed
US-20110237571-A1 PHTHALAZINE DERIVATIVES ARALDI GIAN-LUCA 2011-09-29 US disclosed
US-20110237571-A1 PHTHALAZINE DERIVATIVES ARALDI GIAN-LUCA 2011-09-29 US disclosed
WO-2008061108-A2 PHTHALAZINE DERIVATIVES FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237571-A1 PHTHALAZINE DERIVATIVES CDK5, HIPK2, PACSIN2 KDR 1539/4885RXFP1 4802/4885AURKA 151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.